drug_type
RELEVANT_DRUG
intervention_type
Biological
drug_description
Human anti-CD25 (IL-2 receptor alpha) monoclonal antibody immunotherapy that blocks IL-2/IL-2R signaling and can deplete CD25+ regulatory T cells via Fc-mediated effector functions (e.g., ADCC); administered intravenously as a single agent.
nci_thesaurus_concept_id
C198991
nci_thesaurus_definition
A human monoclonal antibody directed against CD25 (interleukin-2 receptor subunit alpha; IL-2R alpha; IL-2Ra), with potential antineoplastic activity. Upon administration, anti-CD25 monoclonal antibody BA1106 targets and binds to CD25 expressed on tumor-infiltrating regulatory T (Treg) cells. This may deplete Treg cells in the tumor microenvironment (TME) through antibody-dependent cellular cytotoxicity (ADCC) and prevent immunosuppression, thereby increasing the number of effector T (Teff) cells and enhancing anti-tumor immune responses. CD25, the alpha chain of the IL-2 receptor, is highly expressed on Treg cells but not on Teff cells in tumors.
drug_mesh_term
Antibodies, Monoclonal
drug_category
CYTOTOXIC ANTIBODY
drug_class
Inhibitor
drug_delivery_route
Intravenous
drug_mechanism_of_action
Human anti-CD25 (IL-2Rα) monoclonal antibody that binds CD25 on regulatory T cells, blocks IL-2/IL-2R signaling, and depletes CD25+ Tregs via Fc-mediated effector functions (e.g., ADCC), thereby reducing tumor-associated immunosuppression and enhancing effector T-cell activity.
drug_name
BA1106
nct_id_drug_ref
NCT05650242